期刊文献+

化疗前血清乳酸脱氢酶对去势难治性前列腺癌预后预测价值 被引量:4

Pre-chemotherapy lactate dehydrogenase as a prognostic predictor after docetaxel chemotherapy of castration resistant prostate cancer
原文传递
导出
摘要 目的探讨化疗前血清乳酸脱氢酶(lactate dehydrogenase,LDH)对去势难治性前列腺癌(castration-resistant prostate cancer,CRPC)预后的预测价值。方法回顾性分析2008-01-01-2012-01-01天津医科大学肿瘤医院收治的58例单独使用多西他赛方案化疗CRPC患者的临床资料,根据化疗前LDH水平将所有患者分为高LDH组(LDH>248U/L)和低LDH组(LDH≤248 U/L),比较两组患者的临床病理特点,分析LDH对患者预后的影响。结果58例CRPC患者中,高LDH者28例(48.3%),低LDH者30例(51.7%)。两组中位生存期分别为12和27个月,差异有统计学意义,P<0.001。诊断时TNM分期(χ2=10.035,P=0.002)、Gleason评分(χ2=10.008,P=0.002)、ECOG评分(χ2=5.584,P=0.018)、内脏转移(χ2=13.114,P<0.001)、基线PSA(χ2=5.493,P=0.019)、化疗周期数(χ2=9.501,P=0.002)、PSA反应(χ2=17.215,P<0.001)和基线LDH(χ2=28.394,P<0.001)与CRPC患者预后相关。多因素分析显示,诊断时TNM分期、Gleason评分,化疗前是否内脏转移、化疗周期数、PSA反应和基线LDH是影响患者的独立预后因素,P值均<0.05。结论化疗前高LDH者预后差,化疗前高LDH是CRPC患者的独立预后因素。 OBJECTIVE To evaluate the prognostic value of pre-chemotherapy lactate dehydrogenase(LDH)for castration resistant prostate cancer(CRPC).METHODS A total of 58 CRPC patients who underwent docetaxel?chemotherapy in Tianjin Medical University Cancer Institute and Hospital between January 2008 and January 2012 were enrolled.The patients were categorized into 2groups according to the LDH level before chemotherapy:a high LDH(248U/L)and a low LDH group(≤248U/L).We compared their clinicopathologic characteristics and analyzed the prognostic value of pre-chemotherapy LDH.RESULTS There were 58 CRPC patients,including high LDH group 28 cases and high LDH group 30 cases,the median overall survival were 12 and 27 months,separately,P〈0.05.TNM stage,Gleason score,ECOG score,visceral metastasis,prechemotherapy baseline PSA,the number of chemotherapy cycles and without remission during chemotherapy were associated with the poor prognosis.Multivariate analysis showed that:ATNM stage,Gleason score,visceral metastasis,the number of cycles of chemotherapy,PSA response and LDH level in patients with CRPC were independent risk factors for prognosis in the CRPC treated with docetaxel-based chemotherapy(P〈0.05).CONCLUSION Our study showed that patients with high LDH level had poor prognosis,and preChemotherapy lactate dehydrogenase should be an important independent prognostic factor for patients with CRPC.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2015年第14期1143-1146,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 去势难治性前列腺癌 乳酸脱氢酶 预后 多西他赛 castration-resistant prostate cancer lactate dehydrogenase prognosis docetaxel
  • 相关文献

参考文献16

  • 1Siegel R, Naishadham D, Jema[ A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): ll-30.
  • 2韩苏军,张思维,陈万青,李长岭.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334. 被引量:767
  • 3Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on pros- tate cancer[J]. EurUrol, 2008, 53(1): 68-80.
  • 4Bidard FC, Hajage D, Bachelot T, et al. Assessment of cireu lating tumor cells and serum markers for progression-free surviv al prediction in metastatic breast cancer= A prospective observa- tional study[J]. Breast Cancer Res, 2012,14(1):R29.
  • 5Popraeh A, Pavlik T, Melichar B, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cyto-kines[J].Urol 0ncol,2014,32(4) :488-495.
  • 6Meckbach D, Keim U, Richter S, et al. BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy [J/CD]. PLoS One, 2014, 9 (2): e89218.
  • 7Polee MB, Hop WC, Kok TC, et al. Prognostic factors for sur- vival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy [J]. Br J Cancer, 2003,89(11) :2045-2050.
  • 8van Kessel CS, Samim M, Koopman M, et al. Radiological het- erogeneity in response to chemotherapy is associated with poor survival in patients with coloreetal liver metastases[J].Eur J Cancer,2013,49(11) :2486-2493.
  • 9Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II : treatment of advanced, relapsing, and castration resistant prostate cancer[J]. Eur Urol, 2014,65 (2) ,467 479.
  • 10Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase 1I clinical trials in androgen independent prostate cancer: recommendations t'rom the prostate-specific antigen working group[J]. J Clin Oncol, 1999, 17(ll): 3461-3467.

二级参考文献5

  • 1赫杰,赵平,陈万青.2011中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:2-5,26 -37,74 -75.
  • 2Segi M. Cancer mortality for selected sites in 24 countries(1950-57 ) [ M ]. Japan : Department of Public Health,Tohoku Univer-sity of Medicine, 1960.
  • 3FerlayJ, Shin HR, Bray F, et al. Estimates of worldwide burdenof cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010,127(12) : 2893 -2917.
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin’2011,61(2) :69 -90.
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J].CA Cancer J Clin,2012,62( 1) :10 - 29.

共引文献766

同被引文献66

  • 1邹自灏,刘平,李育斌,钟剑峰,黄伟佳,潘兆君.多西他赛联合泼尼松治疗激素难治性前列腺癌的近期疗效[J].中国老年学杂志,2014,34(7):1792-1793. 被引量:3
  • 2叶定伟,张海梁,姚旭东,张世林,戴波,沈益君,朱耀,朱一平,陈羽,夏峥嵘.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌[J].中国癌症杂志,2007,17(3):236-239. 被引量:19
  • 3Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA CancerJClin 2015; 65(2): 87-108.
  • 4Vander Heiden MG, Cantley LC, Thompson CB Understanding the warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324(5930): 1029-1033.
  • 5Augoff K, Hryniewicz-Jankowska A, Tabola R Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer. CanaerLett 2015; 358(1): 1-7.
  • 6Yu Y, Deck JA, Hunsaker LA, et al. Selective active site inhibitors of human lactate dehydrogenases a4, b4, and c4. Biochem Pharmaco12001; 62(1 ): 81-89.
  • 7Li J, Zhu S, Tong J, et al. Suppression of lactate dehydrogenase a compromises tumor progression by downregulation of the warburg effect in glioblastoma. Ncuromport 2016; 27(2): 110-115.
  • 8Chen CY, Feng Y, Chen JY, etal. Identification of a potent inhibitor targeting human lactate dehydrogenase a and its metabolic modulation for cancer cell line. Bioorg McdChem Lett 2016; 26(1): 72-75.
  • 9Wulaningsih W, Holmberg L, Garmo H, et al. Serum lactate dehydrogenase and survival following cancer diagnosis. BrJCancer 2015; 113(9): 1389-1396.
  • 10Naruse K, Yamada Y, Aoki S, etal. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hl"nyokika Kiyo 2007; 53(5): 287-292.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部